Introduction
Therapy with immunotoxins (IT, bacterial or plant derived toxins fused to antibodies) was hampered by systemic toxicity, vascular leak syndrome, hepatocyte injuries and high immunogenicity resulting in humoral immune responses lowering serum half-life and efficacy after a single dose. [1] [2] [3] Antibody humanization, phage display and human IgG transgenic mice have alleviated the immunogenicity problem for the targeting component. 4 Ranpirnase (Onconase  ), a frog analog of human pancreatic RNase A with low immunogenicity, presently is in phase III clinical trial as a single agent therapeutic for unresectable mesothelioma. 5 Pioneered by Susanna Rybak, chemical conjugates of antibodies with Ranpirnase were developed ("Targeted RNases", TR). 6 The anti-neoplastic potency of an Ranpirnase::antiCD22-IgG TR matched that of a conventional anti-CD22-immunotoxin employing Pseudomonas exotoxin in tumor bearing SCID mice, but the total cumulative dose could be increased by more than an order of magnitude. 7, 8 To avoid production and purification issues associated with chemical conjugation, genetic fusions of antibody and RNase were proposed, including RNases of human origin, which cause less concern about immunogenic response. [9] [10] [11] [12] Despite the safety concerns about the use of constructs with bacterial and plant toxins for the repeated treatments usually required in cancer therapy, respective fusion proteins are usually difficult to produce. In general, IT and TR had to be produced in prokaryotic expression systems due to their cytotoxicity on eukaryotic cells. The necessary refolding protocols lead to suboptimal yields of functional protein within the low µg/L range. 13, 14 Purification of soluble IT from the periplasm of E. coli only slightly increased the yield, but the yield remained below mg/L. 15, 16 Only very recently, have there been two reports describing TR production of CD30-scFv-angiogenin and CD22scFv-angiogenin in mammalian expression systems for the first time -but still with a yield not indicated or below mg/L. 17, 18 only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From CD30, a 120 kDa transmembrane type I glycoprotein, was described for the first time as being an immunopathological relevant tumor marker for Hodgkin and Reed-Sternberg cells of Hodgkin lymphomas (HL). 19 The CD30 expression is not restricted to HL but is also present on highly malignant anaplastic large cell lymphomas (ALCL) and adult T-cell lymphomas (ATL) categorized as Non-Hodgkin-Lymphomas (NHL). Beside neoplasms, expression of CD30 in normal cells is restricted to activated B and T lymphocytes with no expression on non-hematolymphoid cells and resting hematolymphoid cells. 19, 20 Due to its characteristic repetitive cystein rich regions within the extracellular domain, CD30 belongs to the tumor necrosis factor receptor (TNFR) superfamily. 21 While inducing cell proliferation and activation by activating transcription factor NF-κB of HL cells, CD30 signaling may induce inhibition of cell growth of ALCL and other CD30 + cells. [22] [23] [24] [25] The frequency of CD30 malignancies is 4 (HL) to 15 (NHL) cases/100000/year. Standard treatment of CD30 + lymphomas is radiation therapy and chemotherapy such as BEACOPP or ABDV. [26] [27] [28] [29] However, 20% of HL cases either relapse after first treatment or are refractory to initial treatment. 30, 31 In cases of NHL, 20-30% of the patients with ALCL relapse within five years. 32, 33 Therefore, alternative therapies such as anti-CD30 monoclonal Abs (mAbs) and anti-CD30 immunoenzyme fusion proteins could be beneficial in cases where standard treatments of CD30 lymphomas fail. Clinical approaches to engage murine mAbs (BerH2), bispecific antibodies or toxin conjugated antibodies were unsuccessful as they had no longterm benefit, provoked an immune response or induced toxic side effects. [34] [35] [36] Very recently, a fusion protein of an anti-CD30 murine scFv (derived from mAb Ber-H2) was fused to human pancreatic RNase, the fusion protein was successfully produced in Drosophila S2 cells, and inhibited tumor growth both in vitro and in vivo. 37 In this study, a novel fully human antibody::ribonuclease fusion protein (huTR) was generated, which was remarkably well expressed in mammalian cell culture. Its specific antigen recognition, enzymatic ribonuclease activity, cellular uptake and in vitro inhibition of only.
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+ tumor cell line proliferation make it a promising candidate to overcome the adverse safety issues of immunotoxins for the treatment of CD30 + malignancies.
Material and Methods:
Generation of the CD30 specific antibodies and human Targeted RNase variants
The CD30 specific human scFv 4E3 was obtained from a semisynthetic human antibody library (Tomlinson I+J provided The cloning procedure of the CD30 specific scFv-Fc-RNase construct was performed by two consecutive PCRs. In the first step, the cDNA coding for CD30 specific scFv was amplified from pIT2-CD30scFv(4E3), as described above for the scFv-RNase construct, and 
Production and purification of CD30 specific antibodies and huTR variants
Production of all CD30 specific huTR and antibody variants except αCD30scFv was done in mammalian HEK293T cells, transfected using HEKfectin (Biorad, Germany) according to the manufacturer's recommendations. Briefly, one day before transfection HEK293T cells were seeded into petri dishes (10 cm diameter) using DMEM/High Glucose (PAA, Austria) supplemented 1% (w/v) penicillin/streptomycin and 8% (v/v) FCS containing low levels of bovine IgG (Invitrogen, Gibco). Supernatants were harvested every 48 h and combined.
Purification of all proteins containing an Fc domain was performed by affinity chromatography using a 1 mL Protein A HP column on an ÄktaPrime FPLC system (GE Healthcare, Uppsala, Sweden). After loading the supernatant to the column, it was washed with 20 column volumes of phosphate buffered saline (PBS) (pH 7.4). Elution was done by a pH shift with 100 mM citrate buffer (pH 2.6) followed by immediate neutralization of the solution with 1 M Tris buffer (pH 9.0).
Production of αCD30scFv was done in P. pastoris KM71 according to the distributor's instructions with inoculation in BMGY medium before switching to BMMY medium for induction of gene expression followed by an additional incubation for 72 h at 30°C. The only.
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All the samples were analysed for integrity, purity and degradation by SDS-polyacrylamide gel electrophoresis (PAGE) and silver staining as well as by Western blot and immunostaining using an alkaline phosphate (AP) conjugated goat anti-human IgG (Fcspecific) antibody except αCD30scFv which was detected via an anti-pentaHis primary antibody (Qiagen, Hilden, Germany). Protein samples were dialyzed against PBS (pH 7.4) and stored at -20°C. Protein concentration was determined using the Bradford assay (BioRad) and BSA as protein standard.
Gel filtration
Molecular mass of αCD30scFv and αCD30scFv-RNase as well as of bivalent antibodies (αCD30scFv-Fc and IgG) and TR constructs (αCD30scFv-RNase-Fc and αCD30scFv-FcRNase) was analysed on a calibrated Superdex-200 10/300 (GE Healthcare) with PBS (pH 7.4), at a flow rate of 1 mL/min. Samples were fractionated and stored for further analysis at 4°C.
Binding Studies:

Affinity and kinetics measurements
Affinity measurements were performed by surface plasmon resonance analysis (SPR) using a Biacore2000 and a CM5 chip (Biacore, Uppsala, Sweden). 
Results
Generation and production of CD30 specific antibody and targeted RNase variants
As binding moiety for all constructs, a phage display derived human CD30 specific scFv fragment was used, in which the V H and V L regions are joined via a 15-amino acid residues linker (Gly 4 -Ser) 3 . Based on this scFv fragment, several human antibody formats (scFv, scFv- For For Table 1 .
Determination of binding kinetics (k on , k off , K D ) by Surface Plasmon Resonance
The antigen binding properties of TR are crucial for their in vitro and in vivo activity. In order to select the most suitable antibody format for the huTR constructs, binding of each of the purified antibody and TR formats to immobilized soluble CD30-Fc was analysed by measuring the binding kinetics via plasmon resonance (Table 1) . No unspecific binding to immobilized control antigen (hen egg lyzozyme) was detectable and mass transfer limitations were not present at the flow rate of 25 µL/min. Due to high dissociation rates, affinity of the monovalent scFv and surprisingly also the bivalent IgG 1 format had to be determined at equilibrium state. K D values of IgG and scFv variants were between 3 and 85-fold worse compared to the scFv-Fc which had an affinity of 6.7x10 -9 M. Consequently, IgG 1 was ruled out as antibody moiety for the TR setup due to superior binding properties of the scFv-Fc format. The affinity of the scFv-Fc based TR proteins to CD30 was found to be in the low nM to high pM range (scFv-RNase-Fc: 7.43x10 -10 M; scFv-Fc-RNase: 9.81x10 -10 M; Figure 3A ).
Binding to native CD30 on lymphoma cell lines
In order to mediate cytotoxicity, huTR derivatives must bind to the native antigen on tumor cells and in addition, they must be internalized and released into the cytoplasm of the target cells. We used flow cytometry to analyse binding of the remaining huTR formats αCD30scFv-RNase and αCD30scFv-Fc-RNase as well as the respective un-fused antibody Figure 4 ).
Internalization of αCD30scFv-Fc-RNase by CD30 + Karpas-299 cells
An earlier report on CD30 malignancies already indicated receptor-mediated endocytosis of antibody bound to CD30. 40 To confirm cellular uptake of the huTR, CD30 + tumor cell lines were incubated with huTR (25 µg/mL) for 1 h at 37°C or 4°C. Incubation at 4°C was done to evaluate dependency of internalization on metabolic activity, which is characteristic for receptor mediated endocytosis. The huTR was detected via fluorescently labelled antibody in confocal LASER scanning microscopy ( Figure 5 ). Depending on the incubation temperature, different distribution patterns were found. After incubation at 4°C, the huTR staining was uniformly localized on the plasma membrane which is particularly visible around the cell shape. On the other hand, cell samples incubated at 37°C showed intracellular staining with a pattern typical for a vesicular pathway after receptor mediated internalization. Controls with CD30 -HD-MY-Z cells lacked any huTR uptake.
In vitro cytotoxic effects of huTR
To assess the in vitro cytotoxicity of the αCD30scFv-Fc-RNase huTR construct, the CD30 
Stability of huTR
To assess the stability, the scFv-Fc-RNase and its antibody moiety scFv-Fc were incubated in 
Discussion
Immunoenzymes combining the specificity of antibodies with enzymes catalysing cytotoxic reactions are promising for the immunotherapy of tumor diseases. 41, 42 However, therapeutic approaches with recombinant immunotoxins employing plant or bacterial toxins suffer from severe side effects caused by high immunogenicity and non-specific cytotoxicity. 43, 44 RNases do not mediate these side effects but nevertheless are highly cytotoxic if they can find their way into the cytoplasm of a target cell. Several RNases can directly mediate anti-tumor effects but most of them require dimerisation or at least modifications which prevent binding of the cytosolic RNase inhibitor. The fusion of RNases with tumor specific antibodies or other tumor binding ligands resulted in enhanced tumor targeting of RNases. 6, 9 In this study we generated a novel, completely human Targeted RNase (huTR) construct with specificity towards CD30 + lymphoma cells. As an effector RNase, we used human pancreatic RNase which has been proven to kill tumor cells after being internalised via CD71. In that study, the RNase-scFv fusion protein was very difficult to produce, it required tedious refolding from E. coli inclusion bodies, and yields of functional molecules were very poor.
Second, the CD71 target -being responsible for the transferrin internalisation and thus iron supply, is not a good prototype for a tumor target, as it is present in high copy number on the surface and has a very high internalisation rate. To cure these problems, we generated various variants binding to the lymphatic tumor antigen CD30 and compared them in respect of (I) specificity and sufficient affinity for CD30 antigen on CD30 + lymphoma cells, (II) receptormediated internalization and (III) specific cytotoxicity to CD30 + tumor cell lines.
Interestingly, the kinetics measurement by surface plasmon resonance indicated that by conversion into the IgG format no major decrease of the dissociation rate due to expected bivalent binding was obtained compared to the monovalent scFv format. In contrast, the bivalent scFv-Fc format showed a significantly slower dissociation rate resulting in a ~85 fold increase of affinity/avidity (to a K D of 6 nM) in comparison to the monovalent scFv format.
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According to these results, the conversion of the scFv fragment into the IgG format probably led to an improper conformational arrangement of the V regions resulting in a loss of affinity which could not be compensated by avidity. Therefore, the IgG format was excluded from further testing as TR construct. Of the other various constructs we tried, only the scFv-RNase and scFv-Fc-RNase construct with C-terminally fused RNase showed RNase activity in vitro, while embedding the human pancreatic RNase between scFv and Fc in the scFv-RNase-Fc construct completely abolished its enzymatic activity (data not shown). Furthermore, the scFv-Fc-RNase is stable in serum at 37°C.
An affinity of 0.6 nM has been described for the human CD30 specific mAb 5F11 (MDX-060) which is derived from the human monoclonal antibody (HuMAb) mouse. 45 Both bivalent huTR constructs using phage display derived antibody fragments from our study showed a similar apparent affinity of 0.8 -1 nM. Interestingly, the addition of the RNase domain improved the affinity by a factor of 7-8. This effect cannot result from additional multimerisation as it should have been observed in size exclusion chromatography. However dimeric RNase reported to have improved tumor binding by itself. 46, 47 In contrast to the insufficient binding of the monovalent scFv-RNase, both the scFv-Fc and scFv-Fc-RNase protein showed strong specific binding to CD30 + Karpas-299 cells.
Interestingly, the binding was slightly increased for RNase fusion protein, also on a CD30 -lymphoma cell line, which could be due to the intrinsic binding capacity of the RNase domain to tumor cell lines. 46,47. Internalization experiments demonstrated the uptake of the scFv-Fc-RNase by CD30 + Karpas-299 cells at 37°C whereas at 4°C the huTR molecules remained at the cell surface. The distribution pattern was typical for receptor mediated endocytosis. 48, 49 After endocytosis, the translocation into the cytosol necessary for cytotoxic activity most likely occurs from the endosome. 52 However, sensitivity of this construct to the cytosolic RI was apparent, but could be neutralized by entering the tumor cells in access.
11
In this study we found that the scFv-Fc-RNase format was most favourable for the construction of an entirely human CD30 specific Targeted RNase, allowing production of significant amounts in mammalian cell culture. The format can be used as a prototype to SDS-PAGE analysis of αCD30 antibody variants and huTR after Protein L (scFv, scFvRNase) or Protein A purification. SDS-PAGE was performed under reducing conditions followed by silver staining (A) or western blot analysis using RNase specific polyclonal rabbit serum and anti-rabbit IgG AP conjugate (B) or using human Fc specific IgG AP conjugate (C) for detection. Receptor mediated internalization was analysed by confocal LASER scanning microscopy. only.
